BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 36579455)

  • 1. Real-world treatment patterns and outcomes of triple-class treated patients with multiple myeloma in the United States.
    Varughese P; Smith R; Xue M; Dorrow N; Hogea C; Maiese EM; Buckingham T
    Expert Rev Hematol; 2023 Jan; 16(1):65-74. PubMed ID: 36579455
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment patterns and overall survival of patients with double-class and triple-class refractory multiple myeloma: a US electronic health record database study.
    Wang PF; Yee CW; Gorsh B; Zichlin ML; Paka P; Bhak RH; Boytsov N; Khanal A; Noman A; DerSarkissian M; Ferrante S; Duh MS
    Leuk Lymphoma; 2023 Feb; 64(2):398-406. PubMed ID: 36408998
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Medicare characteristics, treatment, cost and survival in triple class exposed relapsed or refractory multiple myeloma.
    Hlavacek P; Schepart A; Silverstein AR; Petrilla AA; Johnson W; Schroeder A
    Future Oncol; 2023 Apr; 19(11):775-787. PubMed ID: 37132520
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-world treatment patterns, healthcare use and costs in triple-class exposed relapsed and refractory multiple myeloma patients in the USA.
    Madduri D; Hagiwara M; Parikh K; Pelletier C; Delea TE; Kee A; Chari A
    Future Oncol; 2021 Feb; 17(5):503-515. PubMed ID: 33522834
    [No Abstract]   [Full Text] [Related]  

  • 5. Treatment Patterns and Outcomes in Triple-Class Exposed Patients With Relapsed and Refractory Multiple Myeloma: Findings From the Multinational ITEMISE Study.
    Dhanasiri S; Hollier-Hann G; Stothard C; Dhanda DS; Davies FE; Rodriguez-Otero P
    Clin Ther; 2021 Nov; 43(11):1983-1996.e3. PubMed ID: 34736769
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization and Outcomes of Spanish Patients With Relapsed/Refractory Multiple Myeloma Included in the LocoMMotion Study.
    Mateos MV; Weisel K; Diels J; Arribas A; Tamayo M; Schecter JM; Roccia T; Haddad I; Pacaud L; Moreau P
    Clin Lymphoma Myeloma Leuk; 2024 Apr; 24(4):224-231.e2. PubMed ID: 38212206
    [TBL] [Abstract][Full Text] [Related]  

  • 7. KarMMa-RW: comparison of idecabtagene vicleucel with real-world outcomes in relapsed and refractory multiple myeloma.
    Jagannath S; Lin Y; Goldschmidt H; Reece D; Nooka A; Senin A; Rodriguez-Otero P; Powles R; Matsue K; Shah N; Anderson LD; Streetly M; Wilson K; Le HV; Swern AS; Agarwal A; Siegel DS
    Blood Cancer J; 2021 Jun; 11(6):116. PubMed ID: 34145225
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selinexor plus low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma previously treated with an immunomodulatory agent and a proteasome inhibitor (MARCH): a phase II, single-arm study.
    Qiu L; Xia Z; Fu C; Chen W; Chang C; Fang B; An G; Wei Y; Cai Z; Gao S; Weng J; Chen L; Jing H; Li F; Liu Z; Chen X; Liu J; Wang A; Yu Y; Xiang W; Lynch K; Yu Z; Fu W
    BMC Med; 2022 Apr; 20(1):108. PubMed ID: 35379237
    [TBL] [Abstract][Full Text] [Related]  

  • 9. LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma.
    Mateos MV; Weisel K; De Stefano V; Goldschmidt H; Delforge M; Mohty M; Cavo M; Vij R; Lindsey-Hill J; Dytfeld D; Angelucci E; Perrot A; Benjamin R; van de Donk NWCJ; Ocio EM; Scheid C; Gay F; Roeloffzen W; Rodriguez-Otero P; Broijl A; Potamianou A; Sakabedoyan C; Semerjian M; Keim S; Strulev V; Schecter JM; Vogel M; Wapenaar R; Nesheiwat T; San-Miguel J; Sonneveld P; Einsele H; Moreau P
    Leukemia; 2022 May; 36(5):1371-1376. PubMed ID: 35332278
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real world data on outcomes of anti-CD38 antibody treated, including triple class refractory, patients with multiple myeloma: a multi-institutional report from the Canadian Myeloma Research Group (CMRG) Database.
    Visram A; De La Torre A; White D; Su J; Masih-Khan E; Chu M; Jimenez-Zepeda V; McCurdy A; LeBlanc R; Song K; Mian H; Louzada M; Sebag M; Bergstrom D; Stakiw J; Reiman A; Kotb R; Aslam M; Venner C; Kaedbey R; Gul E; Reece D
    Blood Cancer J; 2023 Dec; 13(1):181. PubMed ID: 38065967
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Practice patterns and outcomes for triple-class exposed patients with relapsed/refractory multiple myeloma in Japan.
    Iida S; Nakakoji M; Spanopoulos D; Okazuka K; Parulekar V; Ishida T
    Future Oncol; 2022 Nov; ():. PubMed ID: 36331578
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Carfilzomib, cyclophosphamide, and dexamethasone (KCd) for the treatment of triple-class relapsed/refractory multiple myeloma (RRMM).
    Pennipede D; Mohyuddin GR; Hawkins R; Ganguly S; Shune L; Ahmed N; Mohan M; Cui W; Mahmoudjafari Z; McGuirk J; Atrash S; Abdallah AO
    Eur J Haematol; 2021 Dec; 107(6):602-608. PubMed ID: 34378251
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Iberdomide plus dexamethasone in heavily pretreated late-line relapsed or refractory multiple myeloma (CC-220-MM-001): a multicentre, multicohort, open-label, phase 1/2 trial.
    Lonial S; Popat R; Hulin C; Jagannath S; Oriol A; Richardson PG; Facon T; Weisel K; Larsen JT; Minnema MC; Abdallah AO; Badros AZ; Knop S; Stadtmauer EA; Cheng Y; Amatangelo M; Chen M; Nguyen TV; Amin A; Peluso T; van de Donk NWCJ
    Lancet Haematol; 2022 Nov; 9(11):e822-e832. PubMed ID: 36209764
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recent real-world treatment patterns and outcomes in US patients with relapsed/refractory multiple myeloma.
    Bruno AS; Willson JL; Opalinska JM; Nelson JJ; Lunacsek OE; Stafkey-Mailey DR; Willey JP
    Expert Rev Hematol; 2020 Sep; 13(9):1017-1025. PubMed ID: 32844683
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advances in targeted therapy for the treatment of patients with relapsed/refractory multiple myeloma.
    Le Ray E; Jagannath S; Palumbo A
    Expert Rev Hematol; 2016 Jan; 9(1):91-105. PubMed ID: 26558304
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Matching-Adjusted Indirect Treatment Comparison to Assess the Comparative Efficacy of Ciltacabtagene Autoleucel in CARTITUDE-1 Versus Belantamab Mafodotin in DREAMM-2, Selinexor-Dexamethasone in STORM Part 2, and Melphalan Flufenamide-Dexamethasone in HORIZON for the Treatment of Patients With Triple-Class Exposed Relapsed or Refractory Multiple Myeloma.
    Weisel K; Krishnan A; Schecter JM; Vogel M; Jackson CC; Deraedt W; Yeh TM; Banerjee A; Yalniz F; Nesheiwat T; Van Sanden S; Diels J; Valluri S; Usmani SZ; Berdeja JG; Jagannath S; Martin T
    Clin Lymphoma Myeloma Leuk; 2022 Sep; 22(9):690-701. PubMed ID: 35764490
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An evaluation of isatuximab, pomalidomide and dexamethasone for adult patients with relapsed and refractory multiple myeloma.
    Piggin A; Prince HM
    Expert Rev Hematol; 2021 May; 14(5):419-427. PubMed ID: 33945375
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Daratumumab plus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma.
    Chari A; Martinez-Lopez J; Mateos MV; Bladé J; Benboubker L; Oriol A; Arnulf B; Rodriguez-Otero P; Pineiro L; Jakubowiak A; de Boer C; Wang J; Clemens PL; Ukropec J; Schecter J; Lonial S; Moreau P
    Blood; 2019 Aug; 134(5):421-431. PubMed ID: 31113777
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment Options for Triple-class Refractory Multiple Myeloma.
    Mikhael J
    Clin Lymphoma Myeloma Leuk; 2020 Jan; 20(1):1-7. PubMed ID: 31767529
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of retreatment with immunomodulatory drugs and proteasome inhibitors following daratumumab monotherapy in relapsed and refractory multiple myeloma patients.
    Oostvogels R; Jak M; Raymakers R; Mous R; Minnema MC
    Br J Haematol; 2018 Oct; 183(1):60-67. PubMed ID: 30080247
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.